Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of “Hold” by Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has received a consensus recommendation of “Hold” from the twelve research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $13.1429.

A number of analysts have recently weighed in on JSPR shares. UBS Group started coverage on shares of Jasper Therapeutics in a research note on Monday, March 23rd. They issued a “neutral” rating for the company. Royal Bank Of Canada set a $3.00 price target on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a research note on Friday, May 15th. TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Tuesday, April 21st.

Institutional Trading of Jasper Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in JSPR. Goldman Sachs Group Inc. lifted its stake in Jasper Therapeutics by 11.2% during the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock valued at $1,005,000 after purchasing an additional 23,453 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Jasper Therapeutics during the first quarter valued at approximately $46,000. JPMorgan Chase & Co. lifted its stake in Jasper Therapeutics by 1,074.7% during the second quarter. JPMorgan Chase & Co. now owns 65,088 shares of the company’s stock valued at $361,000 after purchasing an additional 59,547 shares during the last quarter. XTX Topco Ltd acquired a new stake in Jasper Therapeutics during the second quarter valued at approximately $152,000. Finally, Marshall Wace LLP acquired a new stake in Jasper Therapeutics during the second quarter valued at approximately $281,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Trading Up 6.6%

Shares of NASDAQ:JSPR opened at $0.87 on Friday. The company has a 50 day moving average of $0.97 and a 200-day moving average of $1.39. The firm has a market cap of $24.43 million, a P/E ratio of -0.27 and a beta of 3.07. Jasper Therapeutics has a twelve month low of $0.62 and a twelve month high of $7.19.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. Equities research analysts forecast that Jasper Therapeutics will post -1.81 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.